Drug Profile


Alternative Names: Ciclosporin G; Cyclosporin G; Nva2 cyclosporine; NVal CyA; OG 37325; SDZ 37325

Latest Information Update: 13 Oct 1997

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Ciclosporins
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatic disorders; Systemic lupus erythematosus; Transplant rejection

Most Recent Events

  • 13 Oct 1997 Clinical data have been added to the pharmacokinetic and pharmacodynamic sections.
  • 21 Jun 1996 A study has been added to the pharmacodynamics section
  • 19 Apr 1996 Discontinued-II for Systemic lupus erythematosus in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top